SCHEMBL7182956

SCHEMBL7182956

CC(=O)OCC1(Nc2ccc(C#N)cc2N)CCCC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
CYP3A4 P08684 3/20 0.35
CYP2C19 P33261 3/20 0.35
HSD17B10 Q99714 2/20 0.35
MAPK1 P28482 1/20 0.35
CYP2D6 P10635 2/20 0.34
CYP2C9 P11712 2/20 0.34
USP2 O75604 1/20 0.34
MAP2K1 Q02750 6/20 0.34
EGLN1 Q9GZT9 1/20 0.33
CTSL P07711 3/20 0.32
CTSK P43235 3/20 0.32
CETP P11597 1/20 0.32
CTSS P25774 1/20 0.32
CTSC P53634 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7179553 0.83 MAPT (0.44) ALDH1A1KDM4EGAACTSK
SCHEMBL7191231 0.71 PTGER4 (0.48) ALDH1A1KDM4EGAAHSD17B10
SCHEMBL7183015 0.71 KDM4E (0.44) ALDH1A1KDM4EGAAMAP2K1
SCHEMBL7183531 0.71 ALDH1A1 (0.41) ALDH1A1KDM4EGAAMAP2K1
SCHEMBL7185647 0.71 KDM4E (0.44) ALDH1A1KDM4EGAAMAP2K1
SCHEMBL7188673 0.70 GAA (0.39) ALDH1A1KDM4EGAAMAP2K1KCNH2
SCHEMBL7190795 0.70 GAA (0.39) ALDH1A1KDM4EGAAMAP2K1KCNH2
SCHEMBL7387168 0.69 KDM4E (0.51) ALDH1A1KDM4EGAACYP2C19
SCHEMBL13364155 0.66 ALDH1A1 (0.39) ALDH1A1CYP3A4CYP2C19HSD17B10MAPK1
SCHEMBL15595142 0.66 LMNA (0.44) ALDH1A1KDM4EGAAMAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed